Not Yet RecruitingN/AOther
Biomarker Discovery for Suicide Precision Circuit Therapeutics
Sponsored by Massachusetts General Hospital
NCT ID
NCT07723066
Target Enrollment
60 participants
Start Date
2026-07
Est. Completion
2030-08-31
About This Study
This is a prospective observational biomarker study assessing changes in clinical, behavioral, neuroimaging, and neurophysiological measurer following ketamine/esketamine or electroconvulsive therapy (ECT) in adults with suicidal thoughts or behaviors.
Conditions Studied
Eligibility
Age:18 Years - 65 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * Adults aged 18 to 65 years * Diagnosis of a major depressive episode associated with Major Depressive Disorder or Bipolar Disorder * Presence of moderate to severe suicidal thoughts or behaviors, as determined by the Beck Scale for Suicide Ideation (BSSI) * Scheduled to receive an acute treatment course of electroconvulsive therapy (ECT), intravenous ketamine, or intranasal esketamine as part of routine clinical care * Ability and willingness to provide informed consent Exclusion Criteria: * Neurological disorders, particularly conditions associated with known structural brain lesions * Inability to meet MRI safety requirements * Current alcohol dependence * Active symptoms of non-alcohol psychoactive substance withdrawal